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Abstract 
The transmetallation reaction between zinc dithiocarbamates and rhenium 
carbonyls has been used as a new strategy to link biomolecules to transition metals.  
The zinc(II) dithiocarbamate of isonipecotic acid (1) and the succinimidyl ester 
derivative (2) were prepared by straight forward procedures and were fully 
characterized by spectroscopic and X-ray diffraction methods, showing in both cases the 
presence of dinuclear complexes. Complex 2 reacted with all the primary and secondary 
amines studied (glycine methyl ester, β-alanine methyl ester, 1-(2-methoxy-
phenyl)piperazine and D-(+)-glucosamine) through the activated succinimidyl ester 
group, linking the metallic fragment with the biomolecule by the formation of a peptidic 
bond, and leading to the respective bioconjugated zinc complexes 3-6. In all cases, these 
zinc complexes could be isolated from the reaction medium by simple precipitation. 
These results evidence the potential of complex 2 to be used as a synthon to link the 
zinc dithiocarbamate fragment to biomolecules that contain an amine group. Complexes 
3-6 were characterized by the usual spectroscopic methods and all data agree with the 
proposed structures, which do not contain significant interactions between the zinc 
fragment and the functional groups of these biomolecules. 
The transmetallation reaction between the zinc complexes 3-6 and the rhenium 
carbonyl [ReBr3(CO)3]2- led to the expected rhenium dithiocarbamates 7-10 with no 
change in the organic dithiocarbamate fragments, confirming the viability of this 
reaction as a tool for linking biomolecules to transition elements. All complexes were 
characterized by spectroscopic methods and the crystal structure of 8 was studied by X-
ray diffraction analysis. All data demonstrated that the biomolecule is positioned far 
away from the fac-{Re(CO)3} fragment and the octahedral coordination around the 
metal is completed by the functionalized dithiocarbamate and a phosphine ligand. 
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Finally, the analysis by ESI-MS spectrometry of the reaction between the zinc 
complex 4 and a water solution of [Re(H2O)3(CO)3]+ at a very low concentration (10 
ppm) showed that the transmetallation reaction took place even though the solubility of 
the zinc complex in water medium was as low as 0.66 ppm. This preliminary result 
supports the viability of this approach for the preparation of rhenium and technetium 
target specific radiopharmaceuticals since the preparation of these compounds are 
always performed in water medium. 
 
 
Introduction 
 
Transmetallation is one of the basic reactions in inorganic chemistry that is 
defined as the exchange of ligands between two metal atoms. It has been used since the 
beginnings of organometallic chemistry as a practical tool to prepare new compounds, 
being based on the substitution of a weak carbon-metal bond such as Hg-C by a stronger 
bond like Zn-C.1 Currently, this reaction continues to be extremely useful in the 
synthesis of new compounds and one pertinent example is the use of silver N-
heterocyclic carbens (NHCs) for the preparation of transition metal carbens.2 
The use of organometallics in biology and medicine, and particularly the search 
for organometallic pharmaceuticals, has become a relevant research topic in the last 
decades.3 In this context, the goal of this study is to apply the transmetallation reaction 
to improve the preparation of organometallic radiopharmaceuticals for Nuclear 
Medicine applications. The transmetallation reaction is currently employed in 
radiopharmacy to produce the organometallic compound (99mTc) sestamibi.4 However, 
in our proposal we use this reaction innovatively for a very different goal. 
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Molecular imaging methods are useful in medicine because they allow the 
visualization of biochemical process in living organisms and can help the diagnosis of 
some diseases by non-invasive techniques. The labeling of biologically active molecules 
with a radionuclide is currently a topic of great interest in radiopharmacy because it can 
lead to specific tracers with potential new applications in oncology,5,6 infection 
imaging,6 neuroreceptor imaging7,8 and other medical specialties. Depending on the 
emission properties of the radionuclide either of two imaging methods can be used, 
Positron Emission Tomography (PET) or Single Photon Emission Computed 
Tomography (SPECT). The radionuclide mainly used for SPECT is Tc-99m,4,8 which 
gives rise to a wide range of radiopharmaceuticals by simple preparation procedures and 
is easily accessible by 99Mo/99mTc generators. 
Furthermore, organometallic radiopharmaceutical chemistry has been greatly 
stimulated in recent years after the development of simple and convenient preparations 
of the aqua ions fac-[99mTc(H2O)3(CO)3]+ and fac-[188Re(H2O)3(CO)3]+. The labile 
properties of water ligands in these cations permit the straight forward preparation of 
new rhenium and technetium radiopharmaceuticals with carbonyl ligands, which exhibit 
small size, high thermodynamic stability, kinetic inertia and high in vivo stability.9 All 
these properties make the fac-{M(CO)3} fragment (M = Tc, Re) an excellent synthon 
for developing new specific tracers with biologically active molecules. Therefore, most 
of the current research work with this metal carbonyl is oriented to the development of 
new bioconjugated compounds.10 However, there are some difficulties that are inherent 
to the preparation of specific tracers with Tc-99m carbonyls. A problematic point 
regarding the preparation of such compounds for radiopharmaceutical application is 
schematically shown in Figure 1.  
(Figure 1) 
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Since the concentration of radioactive metal in the labeling reactions is very low 
(10-7 – 10-8 M), only a very small portion of functionalized biomolecules are in fact 
labeled with the metal carbonyl fragment (functionalized biomolecules have the ability 
to bond to the metal fragment as is shown in the schema). Consequently, in the 
radiopharmaceutical preparation the ratio of labeled biomolecules/ unlabeled 
biomolecules is very low, meaning that the labeled biomolecules must compete with 
unlabeled biomolecules for the receptor sites.11 In order to improve the labeled 
/unlabeled biomolecules ratio in radiopharmaceutical preparations, we have designed a 
new approach that allows two apparently contradictory objectives: (1) a high labeling 
yield (nearly all radioactive metals should be linked to the biomolecule) and (2) a low 
unlabeled biomolecule concentration in the reaction mixture. This new strategy is based 
on using a transmetallation reaction between a zinc complex of the functionalized 
biomolecule which is sparingly soluble in water and the radioactive metal in water 
solution (Scheme 1). 
(Scheme 1) 
This reaction is shifted to the right by the higher thermodynamic stability of 
bonds with the {M(CO)3} fragment (M = Tc, Re) with respect to the zinc atom. 
Concurrently, the concentration of unlabeled biomolecule in the reaction mixture can be 
very low because it is limited by the low solubility of the bioconjugate zinc compound 
in water. 
To this purpose, we designed a new compound based on a derivative of 
isonipecotic acid (Scheme 2) as a key compound in attaining our goal, given its 
following advantages:  
(Scheme 2) 
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(1) The dithiocarbamate of isonipecotic acid has been reported12 and it displays an 
appropriate structure for our purpose because it can lead to very stable, 
symmetric compounds since the amine group in isonipecotic acid is a symmetric 
secondary amine. 
(2) Zinc dithiocarbamates are stable compounds13 that exhibit transmetallation14 
reactions with transition metals. Therefore, a zinc dithiocarbamate with the 
structure shown in Scheme 2 can be useful for the transmetallation reaction 
displayed in Scheme 1.  
(3) The above structure contains a N-hidroxysuccinimidyl ester group suitable for 
coupling reactions with amines in order to link the metal to a biomolecule.15 
Hence, this dithiocarbamate of isonipecotic acid can act as a bifunctional 
chelating agent16 (BFCA) because it can work as a linker between the metal 
(bonded to the dithiocarbamate function) and the biomolecule (bonded by a 
peptidic bond). 
(4) It is expected that the zinc dithiocarbamate derivative of isonipecotic acid will 
show low toxicity. Indeed, isonipecotic acid17 and zinc dithiocarbamates18 are 
involved in pharmacological studies and the dithiocarbamate of isonipecotic acid 
exhibits anti-inflammatory activity.19 
 
 
Results and Discussion 
Zinc(II) dithiocarbamate of isonipecotic acid (1). This compound was 
prepared by reaction between a solution of the sodium dithiocarbamate of isonipecotate 
prepared “in situ” from the amine12 and a water solution of zinc (II) acetate (Scheme 3). 
Complex 1 was obtained with high yield (84 %) and high purity by simple 
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crystallization from the reaction medium. One interesting aspect is that this compound 
is scarcely soluble in water and, as was stated in the introduction, the low solubility of 
zinc compounds may be useful to improve the labeled/unlabeled ratio in 
radiopharmaceutical preparation. Thus, the compound was characterized by NMR 
spectroscopy in D2O but all spectra were recorded at the temperature of 40 ºC in order 
to improve the solubility of 1. All spectroscopic data agree with the proposed structure. 
For instance, the characteristic signals of the dithiocarbamate group are observed in the 
13C NMR (201.8 ppm) and the IR (1493 cm-1, ν(C=N)) spectra is consistent with 
reported data for bidentate metal dithiocarbamates.20 The presence of the isonipecotic 
fragment is evidenced by the 1H NMR spectrum in which all observed signals could be 
assigned to the hydrogen atoms of the heterocycle by means of 2D experiments (COSY, 
HSQC and NOESY) and these assignments agree with reported data for isonipecotic 
acid.21 
(Scheme 3) 
The crystal structure of 1 (Figure 2) shows the formation of the postulated zinc 
dithiocarbamate but also reveals that it is a dinuclear centrosymmetric compound in 
solid state. This is a common arrangement for zinc dithiocarbamates22 although 
monomeric compounds have also been reported.23 The analysis of this structure shows 
that bond distances and angles of the core {Zn2S8} are very similar to previously 
reported data for dinuclear zinc dithiocarbamates with simple alkyl groups such as 
ethyl24 and isopropyl.25 The geometry around the zinc atom is intermediate between 
trigonal bipyramidal and tetragonal pyramidal with four similar Zn-S distances {Zn-S21 
= 2.3433(5) Å, Zn-S12 = 2.3457(6) Å, Zn-S22(i) = 2.3972(5) Å, Zn-S11 = 2.4780(5) Å; 
(i) = equivalent atom by inversion center}, whereas a Zn-S bond is significantly longer 
{Zn-S22=2.8162(5) Å}. Similar values have been reported for zinc 
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diethyldithiocarbamate (2.331 Å, 2.355 Å, 2.383 Å, 2.443 Å, 2.815 Å)24  and zinc 
diisopropyldithiocarbamate (2.335 Å, 2.342 Å, 2.377 Å, 2.454 Å, 2.815 Å).25  
(Figure 2) 
 
Succinimidyl ester of zinc(II) dithiocarbamate of isonipecotic acid (2). 
Although the preparation of succinimidyl ester derivatives from carboxylic acid is a 
well-known process, in most synthetic pathways reported the starting reagent is 
carboxylic acid and this route is unfeasible in our case since dithiocarbamates are not 
stable in acidic medium. This problem was solved using the peptide coupling reagent 
TSTU (N,N,N′,N′-Tetramethyl-O-(N-succinimidyl)uronium tetrafluoroborate, CAS: 
105832-38-0) since it can react directly with the carboxylate group and avoids working 
in acid media (Scheme 4). Furthermore, the preparation procedure by this way is very 
straight forward and convenient because compound 2 can be isolated from the 
dimethylformamide reaction medium by simple precipitation after addition of a mixture 
of ethanol/water, allowing to obtain 2 in high yield (above 95 %) and purity. 
(Scheme 4) 
Spectroscopic data of 2 are fully consistent with the proposed structure. Thus, 
ESI-MS shows the molecular weight increase due to the formation of the succinimidy 
ester group and NMR spectroscopy displays all signals of the succinimidyl fragment, as 
well as the shift of resonances of the isonipecotic fragment atoms closer to the ester 
group like the carbonyl carbon and the hydrogen in position 4 of the piperidine ring. 
Single crystals of 2 could be obtained by recrystallization from acetonitrile. The X-ray 
diffraction analysis corroborated the proposed structure, represented in Figure 3.  
(Figure 3) 
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On comparing this structure with compound 1 the strong similarity between the 
{Zn2S8} cores in both complexes is obvious. This result evidences that the conversion 
of the carboxylate group in 1 to the corresponding succinimidyl ester has a minimum 
influence on the dithiocarbamate group. The coordination around the zinc atoms is 
analogous in both complexes with a Zn-S distance significantly longer than the others 
{Zn-S distances for 2: Zn-S21 = 2.369(2) Å, Zn-S12 = 2. 2.364(3) Å, Zn-S22(i) = 
2.371(2) Å, Zn-S11 = 2.413(2) Å, Zn-S22 = 2.753(2) Å; (i) = equivalent atom by 
inversion center }. 
 
Bioconjugated Zn(II) dithiocarbamates (3-6). As stated in the introduction, 
complex 2 was designed with activated ester groups with the aim of preparing 
bioconjugated compounds by means of a coupling reaction with an amine group of a 
biomolecule. In the first stage, we studied the reaction between 2 and the methyl esters 
of the aminoacids glycine and -alanine as a test for the application of this reaction to 
the preparation of bioconjugated Zn(II) dithiocarbamates (Scheme 5).  
The NMR analysis of the reaction mixture showed that the reaction of 2 with the 
methyl esters of glycine and -alanine is nearly quantitative after a few hours at room 
temperature. Thus, complexes 3 and 4 could be isolated from the reaction mixture by 
the simple addition of a mixture of ethanol-water. This very direct procedure gives pure 
compounds that can be used without recrystallization in subsequent reactions. 
Once the viability of this approach was established with the model compounds 3 
and 4, the 1-(2-methoxy-phenyl)piperazine was chosen as the next reagent to be studied. 
This amine can be viewed as a small biomolecule because compounds with an 
arylpiperazine moiety are useful for binding to 5-HT1A26 serotonergic receptors in the 
central nervous system and radiopharmaceuticals with this fragment27 are highly 
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relevant for the study of neuropsychiatric diseases. Furthermore, since this compound is 
a piperazine derivative, it is useful for testing if the ability of 2 to react with amines can 
be extended to secondary amines. Experimental results confirmed this hypothesis and 
the functionalized zinc dithiocarbamate 5 was prepared following a method as simple as 
that used for the synthesis of the model compounds 3 and 4 and, as we noted with these 
compounds, it was also obtained pure and in good yield (71 %). 
The last compound of this family was prepared by reaction between 2 and the D-
(+)-glucosamine to yield the bioconjugate dithiocarbamate 6. This reagent was chosen 
since obtaining 99mTc-glucose derivatives is a subject of prime interest because these 
compounds could be a more readily available and less expensive alternative to 18F-2-
Deoxy-2-fluoro-D-glucopyranose (FDG) which is currently employed for tumor 
imaging.28 As in previous complexes, 6 was also obtained as a pure compound by a 
similar simple procedure with minor differences due to the different solubility of 
glucose derivatives. 
All synthesized compounds were characterized by the usual spectroscopic and 
spectrometric techniques. The NMR signals corresponding to the isonipecotic fragment 
were observed in all compounds in similar positions to those found for 2, the most 
shifted signal being the resonance in 1H NMR assigned to the hydrogen at position 4 of 
the piperidine ring, which is consistent with the substitution of the succinimidyl ester 
located in the same position by the amide group in 3-6. In addition, the expected signals 
of all amide fragments were observed in 1H and 13C NMR spectroscopy, as well as the 
molecular ion peak (M+Na+) for the functionalized zinc dithiocarbamates 3-6. 
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Rhenium carbonyl compounds prepared by transmetallation reactions (7-
10). The transmetallation reaction between the functionalized zinc complexes 3-6 and 
rhenium was studied with the carbonyl [ReBr3(CO)3]2- as shown in Scheme 6. 
(Scheme 6) 
This reaction is carried out in methanol although the solubility of zinc 
complexes 3-6 is very low in this medium. Thus, the fast conversion of a suspension of 
zinc complexes 3-6 in methanol into a clear solution after the addition of rhenium 
carbonyl is indicative of the driving force of the transmetallation reaction. The 13C 
NMR spectroscopy confirms the nearly quantitative character of this reaction since 
NMR analysis of the reaction mixture shows the complete absence of the signal 
assigned to the carbon atom of dithiocarbamate group linked to zinc ( 204 ppm), and it 
displays a downfield shifted peak ( 210 ppm) assigned to the dithiocarbamate bonded 
to rhenium. 
Carbonyl complexes 7-10 were characterized by the usual spectroscopic and 
spectrometric techniques. The NMR chemical shifts of groups coordinated to rhenium 
metal are consistent with reported data for other [Re(CO)3(SS)(P)] complexes,29 
showing the resonances of coordinated phosphine (31P) and the carbon atom of the 
dithiocarbamate group linked to rhenium. The signals of the characteristic set of fac-
{Re(CO)3} fragments are displayed in the IR spectroscopy and the molecular peaks 
(M+Na+) are observed for complexes 7-10 in ESI-MS spectrometry. Spectroscopic data 
of functional groups linked to dithiocarbamate are similar to those of complexes 3-6, 
showing that the substitution of zinc metal by rhenium has very little influence in the 
biomolecular fragment. 
The crystal structure of complex 8 confirms the proposed structure for rhenium 
complexes, showing a very similar arrangement to those previously reported for other 
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[Re(CO)3(SS)(P)] complexes29,30 (Figure 4). The coordination around rhenium metal 
can be described as a slightly distorted octahedron, in which the main distortion comes 
from the chelated dithiocarbamate that forces the S-Re-S angle to be near 70º. 
(Figure 4) 
A remarkable detail of complexes 7-10 is that two signals of different intensity and with 
similar chemical shift (separated 0.4 – 0.6 ppm) are observed in the 31P NMR spectra 
and an analogous situation is detected for some 1H NMR signals. This phenomenon was 
not observed in previous studies with other [Re(CO)3(SS)(P)] complexes and it suggests 
the presence of two isomers in solution. The shape of this signal evolves with 
temperature and shows the coalescence of the two signals at temperatures of nearly 50 
ºC. This result is consistent with the existence of two isomers differing in the position of 
the biomolecular fragment linked to the C4 atom of the piperidine ring (axial or 
equatorial). The position of this group can be interconverted at low temperatures via 
different mechanisms such as a rotation around the C-N bond of dithiocarbamate.31 No 
separation between the two isomers was possible by HPLC analysis of 7-10 and a sole 
peak was always observed. These results support the hypothesis of a fast conversion 
between the two isomers that makes their separation unviable. 
Although the reaction between the zinc dithiocarbamates 3-6 and the rhenium 
carbonyl [ReBr3(CO)3]2- confirms the viability of the transmetallation reaction, to take 
advantage of this approach in radiopharmacy the reaction must be feasible in aqueous 
medium. With the aim of exploring this possibility, the reaction of an aqueous solution 
of [Re(H2O)3(CO)3]+ at a very low concentration (10 ppm) against the zinc complex 4 
was studied as shown in Scheme 7. Complex 4 and triphenylphosphine were 
successively added as solid compounds to an aqueous solution of [Re(H2O)3(CO)3]+ 
yielding a suspension that was heated and finally centrifuged. The formation of the 
 13
rhenium complex 8 was evidenced by the ESI-MS of the clear water solution that gave a 
unique signal with the isotopic pattern of rhenium. This peak corresponds to the 
molecular signal (M+Na+) previously observed for complex 8. It should be emphasized 
that this reaction runs in aqueous medium although the solubility of the reactants in 
water is very low (the solubility of the zinc complex 4 was measured by Inductively 
Coupled Plasma Optical Emission Spectrometry (ICP-OES) and it was as low as 0.66 
ppm). Consequently, this approach provides a simple method for performing high-yield 
reactions with a low concentration of the reactants in the reaction medium. The 
application of this method to radiopharmacy could provide radiopharmaceuticals with a 
very high labeled biomoloecules/ unlabeled biomolecules ratio (see Figure 1).32  
(Scheme 7) 
 
 
Conclusions 
The zinc dithiocarbamate of isonipecotic acid (1) and its succinimidyl ester (2) 
are new complexes that have been synthesized using simple preparation procedures that 
allow obtaining the desired complex in high yield and purity for use in subsequent 
reactions. The X-ray diffraction analyses of these complexes have shown very similar 
dinuclear structures for both, confirming that there are no relevant interactions between 
the succinimidyl fragment and the metal atom in 2. All these results indicate that 
compound 2 can be an excellent starting material for the conjugation of biomolecules to 
zinc. Hence we established the versatility of complex 2 to act as a synthon for linking 
the zinc dithiocarbamate fragment to molecules that contain a primary or secondary 
amine by the coupling reaction with the succinimidyl ester group. This reaction has 
been performed with glycine, β-alanine, 1-(2-methoxy-phenyl)piperazine and D-(+)-
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glucosamine yielding the zinc complexes 3-6. The low solubility of these complexes, in 
conjunction with the high-yield of the coupling reaction, permits obtaining pure 3-6 by 
simple addition of an alcohol or alcohol-water mixture to the reaction medium. 
The study of the transmetallation reaction between the rhenium carbonyl 
[ReBr3(CO)3]2- and the zinc dithiocarbamates 3-6 has led to the rhenium 
dithiocarbamates 7-10, concording with the higher stability of complexes with an 
element of the third transition series with a d6 configuration with respect to the zinc 
(d10). The crystal structure analysis of 8 was solved, showing a coordination set around 
the rhenium metal similar to that of other [Re(CO)3(SS)(P)] complexes. The study of 
the transmetallation between a very dilute solution of [Re(H2O)3(CO)3]+ (10 ppm) and 
complex 4 has evidenced that this reaction is so favourable that it takes place at very 
low metal concentration although the water solubility of the zinc complex 4 is as low as 
0.66 ppm. This result highlights the potential application of this approach to the 
preparation of radiopharmaceuticals since it can improve the labeled biomolecules/ 
unlabeled biomolecules ratio as the concentration of the zinc labelling reagent in the 
reaction media is limited by its low solubility. If it is true that the radionuclide 
concentration under labelling conditions it is still bellow the solubility of 4, it should be 
noted that complex 4 is just a model compound (-alanine methyl ester derivative) and 
it is reasonable to think that zinc complexes bioconjugated to larger biomolecules may 
show lower solubility. 
 
Experimental Section 
All reactions were performed under nitrogen using standard Schlenk tube 
techniques. Infrared spectra were recorded with a Perkin-Elmer 2000 FT spectrometer. 
The NMR spectra were recorded in the Servei de Ressonància Magnètica Nuclear de la 
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Universitat Autònoma de Barcelona on Bruker DPX-250, DPX-360 and AV400 
instruments. Microanalyses were performed by the Servei d’Anàlisi Química del 
Departament de Química de la Universitat Autònoma de Barcelona. Mass spectra and 
exact mass measurements were respectively obtained on an Esquire 3000 with 
electrospray ionization and an ion trap Bruker Daltonics and on a Bruker microTOFQ 
with electrospray ionization Apollo by Servei d’Anàlisi Química del Departament de 
Química de la Universitat Autònoma de Barcelona. The zinc concentration in water 
solutions was measured by Inductively Coupled Plasma Optical Emission Spectrometry 
(ICP-OES) on Polyscan 61E (Thermo Jarrell Ash) spectrometer by Servei d’Anàlisi 
Química del Departament de Química de la Universitat Autònoma de Barcelona. 
 
Synthesis of complex 1. A solution of NaOH (2.8 g, 70 mmol) in water (70 mL) 
was added to a solution of Isonipecotic acid (4.5 g, 35 mmol) in methanol MeOH (140 
mL) and the resulting solution was cooled at 0 ºC. Carbon disulfide (2.45 mL, 40.9 
mmol) was slowly added to this cold solution and the mixture allowed to stir at this 
temperature for 1h. Next, the cooling bath was removed and the mixture was stirred 
overnight at room temperature. After this time, a solution of zinc acetate (3.8 g, 17.5 
mmol) in water (35 mL) was dropwise added under vigorous stirring to the previous 
mixture for a period of 4 h. The resulting solution was cooled to 4 ºC and colorless 
crystals precipitate after 12-24h. This solid was filtered off, washed with MeOH and 
Et2O, and dried under vacuum giving a white powder (8.1 g, 84 % yield). IR (KBr, cm-
1): 1553 (COO-), 1493 (C-N, S2CN). 1H NMR (D2O, δ in ppm): 4.97 (d, J=12.9 Hz, 2H, 
S2CNCH2eq), 3.32 (dt, J= 12.7 hz, J= 2.7 Hz, 2H, S2CNCH2ax), 2.30 (m, 1H, 
S2CNCH2CH2CH), 1.95 (dd, J= 13.7 Hz, J= 3.3 Hz, 2H, S2CNCH2CH2eq), 1.65 (dq, J= 
13.2 Hz, J= 3.7 Hz, 2H, S2CNCH2CH2ax). 13C NMR (D2O, δ in ppm): 201.8 (S2CN), 
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184.1 (COO-), 52.5 (S2CNCH2), 43.8 (S2CNCH2CH2CH), 29,4 (S2CNCH2CH2). ESI 
MS (negative mode, m/z): 493 (M-Na+). Anal. Calcd. for C14H18N2Na2O4S4Zn·2H2O: C, 
30.35 H, 4.00 N, 5.06 %. Found: C, 30.39 H, 3.91 N, 4.97 %. 
Synthesis of complex 2. N,N,N’,N’-Tetramethyl-O-(N-succinimidyl)uronium 
tetrafluoroborate (TSTU, 256 mg, 0.85 mmol) was added to a solution of complex 1 
(200 mg, 0.36 mmol) and N,N-Diisopropylethylamine DIPEA (13 μL, 0.07 mmol) in 
dry dimethylformamide (DMF, 1 mL). The heterogeneous mixture was stirred for 16 h 
and then 140 mL of a mixture H2O:EtOH (1:1, v/v) was added. The crude precipitated 
was centrifuged and washed with EtOH and Et2O to give a white solid (239 mg, 99 % 
yield) that can be recrystallized from hot acetonitrile. IR (KBr, cm-1): 1736 (C=O, 
Succinimidyl), 1634 (C=O, ester), 1493 (C-N, S2CN). 1H NMR (DMSO-d6, δ in ppm): 
4.73 (d, J= 13.4 Hz, 2H, S2CNCH2eq), 3.53 (t, J= 12.4 Hz, 2H, S2CNCH2ax), 3.22 (m, 1 
H, S2CNCH2CH2CH), 2.83 (s, 4H, Succinimidyl), 2.10 (m, 2H, S2CNCH2CH2eq), 1.70 
(m, 2H, S2CNCH2CH2ax). 13C NMR (DMSO-d6, δ in ppm): 203.4 (S2CN), 170.1 (CO, 
Succinimidyl), 169.8 (CO, ester), 49.9 (S2CNCH2), 36.3 (S2CNCH2CH2CH), 27.4 (CH2, 
Succinimidyl), 25.5 (S2CNCH2CH2). ESI MS (positive mode, m/z): 688.9 (M+Na+). 
Anal. Calcd. for C22H26N4O8S4Zn: C, 39.55; H, 3.92; N, 8.39 %. Found: C, 39.82; H, 
3.83; N, 8.61 %. 
Synthesis of complexes 3-5. Complex 2 (1.0 g, 1.5 mmol) was dissolved in dry 
DMF (10 mL). The appropriate amine (3.8 mmol) and DIPEA (7.5 mmol) was added to 
the solution and the reaction mixture was stirred overnight. A mixture of water and 
EtOH (1:1, v/v) (100 mL) was added and the crude product was centrifuged and washed 
with the same mixture to eliminate the excess of the amine and DIPEA. The product 
was dried under vacuum. 
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Complex 3. (678 mg, 74% yield): IR (KBr, cm-1): 3294 (N-H, amide), 1753 (C=O, 
amide), 1646 (C=O, ester), 1492 (C-N, S2CN). 1H NMR (DMSO-d6, δ in ppm): 8.4 (t, J 
= 5.96 Hz, 1H, NH), 4.8 (d, J= 12.86 Hz, 2H, S2CNCH2eq), 3.8 (d, J = 5.96 Hz, 2H, 
NCH2CO), 3.62 (s, 3H, OCH3), 3.31 (m, 2H, S2CNCH2ax), 2.53 (m, 1H, 
S2CNCH2CH2CH), 1.82 (m, 2H, S2CNCH2CH2eq), 1.58 (m, 2H, S2CNCH2CH2ax). 13C 
NMR (DMSO-d6, δ in ppm): 202.7 (S2CN), 174.6 (CO, amide), 170.6 (NCH2CO), 51.7 
(OCH3), 50.6 (S2CNCH2), 39.9 (S2CNCH2CH2CH), 28.2 (S2CNCH2CH2). ESI MS 
(positive mode, m/z): 637.0 (M+Na+). Anal. Calcd. for C20H30N4O6S4Zn: C, 38.99; H, 
4.91; N, 9.09 %. Found: C, 38.71; H, 4.91; N, 8.92 %. 
Complex 4. (580 mg, 58 % yield): IR (KBr, cm-1): 3271 (N-H, amide), 1746 
(C=O, amide), 1640 (C=O, ester), 1492 (C-N, S2CN). 1H NMR (DMSO-d6, δ in ppm): 
8.0 (t, J = 5.41 Hz, 1H, NH), 4.8 (d, J= 12.6 Hz, 2H, S2CNCH2eq), 3.60 (s, 3H, OCH3), 
3.27 (m, 4H, S2CNCHax, NCH2CH2CO), 2.45 (m, 3H, S2CNCH2CH2CH, 
NCH2CH2CO), 1.76 (m, 2H, S2CNCH2CH2eq), 1.57 (m, 2H, S2CNCH2CH2ax). 13C NMR 
(DMSO-d6, δ in ppm): 202.7 (S2CN), 174.0 (CO, amide), 172.2 (NHCH2CH2CO), 51.8 
(OCH3), 51.1 (S2CNCH2), 40.6 (S2CNCH2CH2CH), 35.1 (NHCH2CH2CO), 34.0 
(NHCH2CH2CO), 28.7 (S2CNCH2CH2). ESI MS (positive mode, m/z): 665.1 (M+Na+). 
Anal. Calcd. for C22H34N4O6S4Zn·H2O: C, 39.90; H, 5.48; N, 8.46 %. Found: C, 39.96; 
H, 5.37; N, 8.41 %. 
Complex 5. (870 mg, 71 % yield): IR (KBr, cm-1): 1639 (C=O, amide), 1436 (C-
N, S2CN). 1H NMR (DMSO-d6, δ in ppm): 6.96-6.89 (m, 4H, ArH), 4.87 (d, J= 12.26 
Hz, 2H, S2CNCH2eq), 3.79 (s, 3H, OCH3), 3.68 (s, 2 H, piperazine ring), 3.60 (s, 2H, 
piperazine ring), 3.40 (m, 2H, S2CNCH2ax), 3.05 (m, 1H, S2CNCH2CH2CH), 2.97 (s, 
2H, piperazine ring), 2.90 (s, 2H, piperazine ring), 1.80 (m, 2H, S2CNCH2CH2eq), 1.59 
(m, 2H, S2CNCH2CH2ax). 13C NMR (DMSO-d6, δ in ppm): 202.6 (S2CN), 172.0 (CO, 
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amide), 152.0-111.9 (ArH), 55.4 (OCH3), 50.8 (piperazine ring), 50.6 (S2CNCH2), 50.2 
(piperazine ring), 45.2 (piperazine ring), 41.4 (piperazine ring), 35.6 
(S2CNCH2CH2CH), 28.3 (S2CNCH2CH2). ESI MS (positive mode, m/z): 843.4 
(M+Na+). Anal. Calcd. for C36H48N6O4S4Zn: C, 52.57; H, 5.88; N, 10.22 %. Found: C, 
52.24; H, 5.82; N, 9.86 %. 
Synthesis of complex 6. The complex 2 (1.0 g, 1.5 mmol) was dissolved in dry 
DMF (10 mL). Glucosamine chlorhydrate (3.8 mmol) and DIPEA (3.8 mmol) was 
added to the solution and stirred for 3 hours. Methanol (100 mL) was added and the 
crude was centrifuged and washed with the same solvent to eliminate the excess of 
glucosamine and DIPEA. The product was dried under vacuum (550 mg, 44% yield): IR 
(KBr, cm-1): 3411 (O-H, alcohols), 1644 (C=O, amide), 1492 (C-N, S2CN). 1H NMR 
(DMSO-d6, δ in ppm): 7.69 (d, J = 8.31 Hz, 1H, NH), 7.64 (d, J = 7.65 Hz, 1H, NH), 
6.47 (d, J = 6.34 Hz, 1H, NHCHCHO), 6.41 (d, J = 4.28 Hz, 1H, NHCHCHO), 4.90-
4.30 (m, 6 H, S2CNCH2eq, glucosamine ring), 3.60-3.40 (m, 5H, S2CNCH2ax, 
glucosamine ring ), 3.31-3.00 (m, 2H, glucosamine ring), 2.56 (m, 1H, 
S2CNCH2CH2CH), 1.71 (m, 2H, S2CNCH2CH2eq), 1.60 (m, 2H, S2CNCH2CH2ax). 13C 
NMR (DMSO-d6, δ in ppm, except glucosamine ring resonances): 192.5 (S2CN), 163.8 
(CO, amide), 51.2 (S2CNCH2), 40.8 (S2CNCH2CH2CH), 28.5 (S2CNCH2CH2). ESI MS 
(positive mode, m/z): 817.2 (M+Na+); Anal. Calcd. for C26H42N4O12S4Zn·2H2O: C, 
37.52; H, 5.57; N, 6.73 %. Found: C, 37.88; H, 5.42; N, 6.69 %. 
Synthesis of complexes 7-10. The precursor [NEt4]2[Re(CO)3Br3] (100 mg, 0.14 
mmol) was dissolved in MeOH (10 mL) and added to a suspension of 3-6 (0.08 mmol) 
in the same solvent (30 mL). The mixture was heated a reflux for 1 h. Next, 
triphenylphosphine (34 mg, 0.14 mmol) was added and the resulting suspension was 
heated to reflux for one additional hour. The obtained clear solution was concentrated 
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under vacuum to 5 mL and the resulting solution was cooled to 4 ºC to crystallize the 
complex. The complex was washed with cold MeOH and Et2O to give a white solid. 
Complex 7 (58 mg, 51 % yield): IR (KBr, cm-1): 2009, 1912, 1905, 1892 (CO), 
1723 (C=O, amide), 1678 (C=O, ester), 1497 (C-N, S2CN). 1H NMR (CDCl3, δ in 
ppm): 7.53-7.28 (m, 15 H, ArH), 5.92 (t, J= 5.07 Hz, 1H, NH), 4.31 (d, J= 13.81 Hz, 
2H, S2CNCH2eq), also observed 4.21 (d, J= 13.81 Hz, 2H, S2CNCH2eq), 4.05 (d, J= 5.07 
Hz, 2H, NCH2CO), 3.81 (s, 3H, OCH3), 2.74 (t, J= 11.96 Hz, 2H, S2CNCH2ax), also 
observed 2.50 (t, J= 11.96 Hz, 2 H, S2CNCH2ax), 2.28 (m, 1H, S2CNCH2CH2CH), 1.67 
(m, 2H, S2CNCH2CH2eq), 1.30 (m, 2H, S2CNCH2CH2ax). 13C NMR (CDCl3, δ in ppm, 
except phenyl resonances): 210.1 (S2CN), 193.2 - 190.4 (carbonyls), 173.7 (amide), 
170.5 (ester), 51.6 (OCH3), 43.4 (S2CNCH2CH2CH), 41.3 (S2CNCH2CH2CH), 40.4 
(NCH2CO), 26.6 (S2CNCH2CH2CH). 31P-NMR (CDCl3, δ in ppm) 14.8, also observed 
14.4. ESI MS (positive mode, m/z): 831.0 (M+Na+); Anal. Calcd. for 
C31H30N2O6PReS2·H2O: C, 45.08; H, 3.91; N, 3.39 %. Found: C, 45.24; H, 4.08; N, 
3.53 %. 
Complex 8 (45 mg, 40% yield): IR (KBr, cm-1): 2009, 1912, 1905, 1892 (CO), 
1723 (C=O, amide), 1678 (C=O, ester), 1497 (C-N, S2CN). 1H NMR (CDCl3, δ in 
ppm): 7.53-7.28 (m, 15 H, ArH), 6.10 (m, 1H, NH), 4.31 (d, J= 13.54 Hz, 2H, 
S2CNCH2eq), also observed 4.21 (d, J= 13.54 Hz, 2 H, S2CNCH2eq), 3.71 (s, 3H, OCH3), 
3.55 (q, J= 5.81 Hz, 2H, NCH2CH2CO), 2.70 (t, J= 13.54 Hz, 2H, S2CNCH2ax), also 
observed 2.40 (t, J= 13.54 Hz, 2 H, S2CNCH2ax), 2.56 (q, J= 5.81 Hz, 2H, 
NCH2CH2CO), 2.17 (m, 1H, S2CNCH2CH2CH), 1.68 (m, 2H, S2CNCH2CH2eq), 1.26 
(m, 2H, S2CNCH2CH2ax). 13C NMR (CDCl3, δ in ppm, except phenyl resonances): 210.9 
(S2CN), 193.2 - 190.4 (carbonyls), 174.2 (amide), 44.5 (S2CNCH2), 34.9 (OCH3), 33.8 
(NCH2CH2CO), 33.7 (NCH2CH2CO), 29.8 (S2CNCH2CH2CH), 27.6 (S2CNCH2CH2). 
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31P-NMR (CDCl3, δ in ppm) 15.3, also observed 14.7. ESI MS (positive mode, m/z): 
845.0 (M+Na+); Anal. Calcd. for C32H32N2O6PReS2: C, 46.76 H, 3.92 N, 3.41 %. 
Found: C, 46.68 H, 4.00 N, 3.34 %. 
Complex 9 (74 mg, 58% yield): IR (KBr, cm-1): 2009, 1912, 1905, 1892 (CO), 
1723 (C=O, amide), 1678 (C=O, ester), 1497 (C-N, S2CN). 1H NMR (CDCl3, δ in 
ppm): 7.55-6.87 (m, 19H, ArH), 4.31 (d, J= 13.05 Hz, 2H, S2CNCH2eq), also observed 
4.21 (d, J= 13.05 Hz, 2H, S2CNCH2eq), 3.88 (s, 3H, OCH3), 3.82 s, 2H, piperazine 
ring), 3.66 (s, 2H, piperazine ring), 3.10 (s, 4H, piperazine ring), 2.77 (t, J= 11.51 Hz, 
2H, S2CNCH2ax), also observed 2.53 (t, J= 11.51 Hz, 2H, S2CNCH2ax), 2.66 (m, 1H, 
S2CNCH2CH2CH), 1.65 (m, 2H, S2CNCH2CH2eq), 1.44 (m, 2H, S2CNCH2CH2ax). 13C 
NMR (CDCl3, δ in ppm, except phenyl resonances): 211.0 (S2CN), 193.4 - 190.3 
(carbonyls), 172.2 (amide), 55.6 (OCH3), 51.4 (piperazine ring), 44.5 (S2CNCH2), 37.6 
(S2CNCH2CH2CH), 27.4 (S2CNCH2CH2). 31P-NMR (CDCl3, δ in ppm) 15.3, also 
observed 14.7. ESI MS (positive mode, m/z): 912.0 (M+H+); Anal. Calcd. for 
C39H39N3O4PReS2·H2O: C, 50.42; H, 4.45; N, 4.52 %. Found: C, 50.55; H, 4.43; N, 
4.52 %. 
Complex 10 (88 mg, 70% yield): IR (KBr, cm-1): 2006, 1915, 1906, 1892 (CO), 
1722 (C=O, amide), 1498 (C-N, S2CN) cm-1; 1H NMR (acetone-d6, δ in ppm): 7.58-7.46 
(m, 15H, ArH), 6.89 (d, J = 8.22 Hz, 1H, NH), 6.86 (d, J = 8.22 Hz, 1H, NH), 5.66 (m, 
1H, NHCHCHO), 5.62 (m, 1H, NHCHCHO), 5.17 (m, 1H, NHCHCHO), 5.10 (m, 1H, 
NHCHCHO), 4.31-3.33 (m, 6H, S2CNCH2eq, glucosamine ring), 2.83 (alcohols), 2.67 
(t, J= 11.04 Hz, 2H, S2CNCH2ax), 2.55 (m, 1H, S2CNCH2CH2CH), 1.73 (m, 2H, 
S2CNCH2CH2eq), 1.56 (m, 2H, S2CNCH2CH2ax). 13C NMR (acetone-d6, δ in ppm, 
except phenyl resonance): 209.8 (S2CN), 194.2 (CO, amide), 91.4 (NHCHCHO), 76.8 
(OCH(OH)CH2OH), 72.2 (NHCHCH(OH)), (NHCHCH(OH)CH(OH)), 61.8 (CH2OH), 
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54.7 (NHCH), 45.4 (S2CNCH2), 42.1 (S2CNCH2CH2CH), 28.3 (S2CNCH2CH2). 31P-
NMR (acetone-d6, δ in ppm) 12.0, also observed 11.6. ESI MS (positive mode, m/z): 
921.1 (M+Na+). Anal. Calcd. for C34H36N2O9PReS2·2H2O: C, 43.72; H, 4.32; N, 3.00 
%. Found: C, 44.02; H, 4.26; N, 3.02 %. 
Synthesis of complex 8 in water medium. A solution of [Re(H2O)3(CO)3]+ (10 
ppm) was prepared according to previously reported method33 and added to a 
suspension of 4 (1 mg, 2 mol) in water (1 mL). The mixture was heated in a boiling 
water bath for 1 h. Next, triphenylphosphine (1 mg, 4 mol) was added and heated in a 
boiling water bath for one additional hour. The solution was centrifuged and analyzed 
by ESI MS. ESI MS (positive ion): 845.0 (M+Na+). 
 Determination of solubility of compounds 3 and 4 in water. A suspension in 
water (10 mL) of the appropriate Zn (II) compound (3-4) (1 mg) was heated to 40 ºC for 
1 hour. Next, the solution was filtered through 0.2 m filter and centrifuged at 13000 
rpm for 20 minutes. The resulting clearly solution was diluted in HNO3 1% and the Zn 
content was analysed by means of Inductively Coupled Plasma Optical Emission 
Spectrometry (ICP-OES). Solubility in water: 3.1 ppm for 3 and 0.66 ppm for 4. 
X-ray Crystallography. Data were collected in Servei de Difracció de Raigs X de 
la UAB using the SMART34 software on a Bruker APEX CCD diffractometer using 
graphite monochromated Mo Kα radiation (λ = 0.71073 Å) at 100K for 2 and at room 
temperature for 1 and 8. Data reductions were performed using the SAINT35 software. 
Data were corrected for absorption using SADABS.36 Structures were solved by direct 
methods using SHELXS-9737 and refined by full-matrix least squares on F2 with 
anisotropic displacement parameters for the non-H atoms using SHELXL-9737 The C- 
and N-hydrogen atoms were included from calculated positions and refined riding on 
their respective carbon or nitrogen atoms with isotropic displacement parameters 
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In the crystal structure of complex 1 MeOH/water disorder is present in one site. 
15 from 18 water hydrogen atoms were located in a difference Fourier map. In the 
crystal structure of complex 2 MeCN is present, dimer/MeCN ratio being 1:3. One 
MeCN molecule is disordered about an inversion center. In the crystal structure of 
complex 8 two molecules with similar conformation are present in the asymmetric unit. 
Details of the structure solution and refinement are provided as Supporting 
Information for complexes 1, 2 and 8. 
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Scheme 7 
 
 
 
Figure captions 
 
Figure 1: Schematic representation of the competition between labeled and unlabeled 
molecules for receptor sites after labeling reaction. 
 
Figure 2: Perspective view of the centrosymmetric dimeric anion 
[Zn2(S2CNC5H9COO)4]4- of complex 1. Hydrogen atoms have been omitted for clarity. 
 
Figure 3: Perspective view of the centrosymmetric dimeric complex 2. Hydrogen atoms 
have been omitted for clarity. 
 
Figure 4: Perspective view of complex 8. Hydrogen atoms have been omitted for 
clarity. 
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